Robert A Preti1, Wai Shun Chan2, Joanne Kurtzberg3, Ronna E Dornsife3, Paul K Wallace4, Rosemary Furlage4, Anna Lin5, Imelda Omana-Zapata5, Halvard Bonig6, Torsten Tonn6. 1. Progenitor Cell Therapy, NeoStem, Allendale, New Jersey, USA. Electronic address: rpreti@progenitorcell.net. 2. Progenitor Cell Therapy, NeoStem, Allendale, New Jersey, USA. 3. Duke University, Pediatric Blood and Marrow Transplantation Program, Durham, North Carolina, USA. 4. Roswell Park Cancer Institute, Buffalo, New York, USA. 5. BD Biosciences, San Jose, California, USA. 6. German Red Cross Blood Service and Institute for Transfusion Medicine and Immunohematology, Goethe University, Frankfurt, Germany.
Abstract
BACKGROUND AIMS: Evaluation of the BD Stem Cell Enumeration Kit was conducted at four clinical sites with flow cytometry CD34(+) enumeration to assess agreement between two investigational methods: (i) the BD FACSCanto II and BD FACSCalibur systems and (ii) the predicate method (Beckman Coulter StemKit and StemTrol, Immunotech SAS, Beckman Coulter, Marseille Cedex 9, France). METHODS: Leftover and delinked specimens (n = 1032) from clinical flow cytometry testing were analyzed on the BD FACSCanto II (n = 918) and BD FACSCalibur (n = 905) in normal and mobilized blood, frozen and thawed bone marrow and leucopheresis and cord blood anticoagulated with citrate phosphate dextrose, anticoagulant citrate dextrose-solution A, heparin and ethylenediaminetetraacetate, alone or in combination. Fresh leucopheresis analysis addressed site equivalency for sample preparation, testing and analysis. RESULTS: The mean relative bias showed agreement within predefined parameters for the BD FACSCanto II (-2.81 to 4.31 ±7.1) and BD FACSCalibur (-2.69 to 5.2 ±7.9). Results are reported as absolute and relative differences compared with the predicate for viable CD34(+), percentage of CD34(+) in CD45(+) and viable CD45(+) populations (or gates). Bias analyses of the distribution of the predicate low, mid and high bin values were done using BD FACSCanto II optimal gating and BD FACSCalibur manual gating for viable CD34(+), percentage of CD34(+) in CD45(+) and viable CD45(+). Bias results from both investigational methods show agreement. Deming regression analyses showed a linear relationship with R(2) > 0.92 for both investigational methods. DISCUSSION: In conclusion, the results from both investigational methods demonstrated agreement and equivalence with the predicate method for enumeration of absolute viable CD34(+), percentage of viable CD34(+) in CD45(+) and absolute viable CD45(+) populations.
BACKGROUND AIMS: Evaluation of the BD Stem Cell Enumeration Kit was conducted at four clinical sites with flow cytometry CD34(+) enumeration to assess agreement between two investigational methods: (i) the BD FACSCanto II and BD FACSCalibur systems and (ii) the predicate method (Beckman Coulter StemKit and StemTrol, Immunotech SAS, Beckman Coulter, Marseille Cedex 9, France). METHODS: Leftover and delinked specimens (n = 1032) from clinical flow cytometry testing were analyzed on the BD FACSCanto II (n = 918) and BD FACSCalibur (n = 905) in normal and mobilized blood, frozen and thawed bone marrow and leucopheresis and cord blood anticoagulated with citrate phosphate dextrose, anticoagulant citrate dextrose-solution A, heparin and ethylenediaminetetraacetate, alone or in combination. Fresh leucopheresis analysis addressed site equivalency for sample preparation, testing and analysis. RESULTS: The mean relative bias showed agreement within predefined parameters for the BD FACSCanto II (-2.81 to 4.31 ±7.1) and BD FACSCalibur (-2.69 to 5.2 ±7.9). Results are reported as absolute and relative differences compared with the predicate for viable CD34(+), percentage of CD34(+) in CD45(+) and viable CD45(+) populations (or gates). Bias analyses of the distribution of the predicate low, mid and high bin values were done using BD FACSCanto II optimal gating and BD FACSCalibur manual gating for viable CD34(+), percentage of CD34(+) in CD45(+) and viable CD45(+). Bias results from both investigational methods show agreement. Deming regression analyses showed a linear relationship with R(2) > 0.92 for both investigational methods. DISCUSSION: In conclusion, the results from both investigational methods demonstrated agreement and equivalence with the predicate method for enumeration of absolute viable CD34(+), percentage of viable CD34(+) in CD45(+) and absolute viable CD45(+) populations.
Authors: Richard C Duggleby; Sergio Querol; Robert C Davy; Laura J Fry; Daniel A Gibson; Roger B V Horton; Salmah N Mahmood; Susana G Gomez; J Alejandro Madrigal Journal: Transfusion Date: 2011-08-24 Impact factor: 3.157
Authors: Maria Nawrot; David H McKenna; Darin Sumstad; John D McMannis; Zbigniew M Szczepiorkowski; Helen Belfield; Elke Grassman; Toni Temples; Deanna Nielsen; Ning Yuan; Bert Wognum; Jo-Anna Reems Journal: Transfusion Date: 2011-05-13 Impact factor: 3.157
Authors: R Vij; R Brown; S Shenoy; J S Haug; D Kaesberg; D Adkins; L T Goodnough; H Khoury; J DiPersio Journal: Bone Marrow Transplant Date: 2000-06 Impact factor: 5.483
Authors: Patrick J Stiff; Ivana Micallef; Auayporn P Nademanee; Edward A Stadtmauer; Richard T Maziarz; Brian J Bolwell; Gary Bridger; Sachin Marulkar; Frank J Hsu; John F DiPersio Journal: Biol Blood Marrow Transplant Date: 2010-11-30 Impact factor: 5.742
Authors: D Robert Sutherland; Rakesh Nayyar; Erica Acton; Angeline Giftakis; Sue Dean; Victoria L Mosiman Journal: Cytotherapy Date: 2009 Impact factor: 5.414
Authors: Vinod K Prasad; Adam Mendizabal; Suhag H Parikh; Paul Szabolcs; Timothy A Driscoll; Kristin Page; Sonali Lakshminarayanan; June Allison; Susan Wood; Deborah Semmel; Maria L Escolar; Paul L Martin; Shelly Carter; Joanne Kurtzberg Journal: Blood Date: 2008-06-27 Impact factor: 22.113
Authors: John Patterson; Cally H Moore; Emily Palser; Jason C Hearn; Daniela Dumitru; Holli A Harper; Ivan N Rich Journal: J Transl Med Date: 2015-03-18 Impact factor: 5.531